OKYO Pharma Limited Sponsored ADR (OKYO) AI Stock Analysis

• Market Cap: $103.43M
• Dividend Yield: N/A
• Average Volume (3M): 164.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 37,610,676
• 10 Day Avg. Volume: 220,430
• 30 Day Avg. Volume: 164,294
• PEG Ratio: 4.36
• Price to Book (P/B): 5.58K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -934.25
• Enterprise Value/Market Cap: 17.98
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 10.00T>
• Enterprise Value/Ebitda: -335.56
• 1Y Price Target: $7.00
• Price Target Upside: 154.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 38 Underperform
• Price Target: ―

OKYO Pharma Limited's stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

Positive Factors

Clinical Trial Success

Positive proof-of-concept data from the Phase 2 trial of urcosimod for the treatment of neuropathic corneal pain was announced by OKYO Pharma.

Regulatory Progress

The FDA granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain, allowing for more frequent meetings and quicker communication with the FDA.

Negative Factors

Financial Risks

The company needs to raise additional capital within the next 12 months to fund operations.

Regulatory Approval Risks

Risks include failure of OK-101 in clinical trials and failure to secure regulatory approval in the U.S.

OKYO Pharma Limited Sponsored ADR Business Overview & Revenue Model

Company Description

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

How the Company Makes Money

OKYO Pharma Limited generates revenue primarily through the development and potential commercialization of its drug candidates. The company makes money by advancing its therapeutic products through clinical trials and ultimately obtaining regulatory approvals to market them. Revenue streams may include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from any successful commercialization of its treatments. Additionally, OKYO may engage in strategic partnerships or collaborations that provide funding and resources to support its research and development efforts.

OKYO Pharma Limited Sponsored ADR Financial Statement Overview

Summary

OKYO Pharma Limited faces significant financial challenges with no revenue generation and negative equity, which presents a high financial risk. Persistent cash outflows due to ongoing R&D investments without profitability improvements remain key concerns.

Income Statement

OKYO Pharma Limited has shown no total revenue over the past years, reflecting the challenges in generating sales typical in the biotechnology industry. Net income remains negative, indicating ongoing operational and developmental expenses without offsetting revenue.

Balance Sheet

The balance sheet indicates a concerning negative stockholders' equity, which is a risk factor for financial stability. The total liabilities exceed total assets, which may affect the company's ability to raise capital. The debt-to-equity ratio cannot be calculated due to negative equity, further highlighting financial risk.

Cash Flow

OKYO's cash flow is characterized by negative operating cash flow and free cash flow, suggesting significant cash burn typical for R&D-focused biotech firms. However, the company has managed to secure financing inflows, which partially mitigates cash flow concerns.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	―	―	-3.80K	-2.42K	-13.09K	―
EBITDA	―	―	-13.18M	-6.21M	-3.35M	-1.51M
Net Income	―	―	-13.27M	-5.43M	-3.35M	-1.54M
Balance Sheet
Total Assets	2.83M	1.54M	5.20M	4.30M	7.09M	597.40K
Cash, Cash Equivalents and Short-Term Investments	987.20K	826.85K	4.05M	2.70M	6.89M	234.96K
Total Debt	1.81K	0.00	2.22M	0.00	98.76K	31.62K
Total Liabilities	10.05M	7.42M	7.26M	1.35M	1.77M	737.20K
Stockholders Equity	-7.23M	-5.88M	-2.05M	2.95M	5.32M	―
Cash Flow
Free Cash Flow	―	-9.49M	-7.70M	-5.47M	-1.61M	-1.20M
Operating Cash Flow	―	-9.49M	-7.70M	-5.47M	-1.60M	-1.20M
Investing Cash Flow	0.00	0.00	-5.92K	-1.67K	-18.11K	-132.67K
Financing Cash Flow	551.81K	6.21M	9.32M	2.15M	7.83M	963.31K

OKYO Pharma Limited Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OKYO, the sentiment is Neutral. The current price of 2.75 is below the 20-day moving average (MA) of 2.78, above the 50-day MA of 2.32, and above the 200-day MA of 1.46, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 54.08 is Neutral, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OKYO.

OKYO Pharma Limited Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TCRX	52 Neutral	$105.82M	―	-78.93%	―	-70.15%	―
Sector *	46 Neutral	C$205.70M	-3.34	-23.14%	2.45%	20.79%	-0.36%
ZURA	43 Neutral	$100.24M	―	-62.34%	―	―	86.65%
OKYO	38 Underperform	$103.43M	―	0.00%	―	―	―
ABOS	36 Underperform	$95.10M	―	-55.68%	―	―	-57.45%
HLVX	35 Underperform	$107.80M	―	-54.64%	―	―	1.27%
BMEA	35 Underperform	$102.64M	―	-156.81%	―	―	-10.99%